Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balance.

MLA

Douxfils, Jonathan, et al. “Fezolinetant: A Novel Nonhormonal Therapy for Vasomotor Symptoms Due to Menopause Requiring a Careful Evaluation of the Benefit-Risk Balance.” Expert Opinion on Pharmacotherapy, vol. 25, no. 14, Oct. 2024, pp. 1971–72. EBSCOhost, https://doi.org/10.1080/14656566.2024.2410398.

APA

Douxfils, J., Beaudart, C., & Dogné, J.-M. (2024). Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balance. Expert Opinion on Pharmacotherapy, 25(14), 1971–1972. https://doi.org/10.1080/14656566.2024.2410398

Chicago

Douxfils, Jonathan, Charlotte Beaudart, and Jean-Michel Dogné. 2024. “Fezolinetant: A Novel Nonhormonal Therapy for Vasomotor Symptoms Due to Menopause Requiring a Careful Evaluation of the Benefit-Risk Balance.” Expert Opinion on Pharmacotherapy 25 (14): 1971–72. doi:10.1080/14656566.2024.2410398.